A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype

Lili Li,Nancy Hamel,Kristi Baker,Michael J McGuffin,Martin Couillard,Adrian Gologan,Victoria A Marcus,Bernard Chodirker,Albert Chudley,Camelia Stefanovici,Anne Durandy,Robert A Hegele,Bing-Jian Feng,David E Goldgar,Jun Zhu,Marina De Rosa,Stephen B Gruber,Katharina Wimmer,Barbara Young,George Chong,Marc D Tischkowitz,William D Foulkes

DOI: https://doi.org/10.1136/jmedgenet-2014-102934

2015-02-17

Journal of Medical Genetics

Abstract:BACKGROUND: Inherited mutations in DNA mismatch repair genes predispose to different cancer syndromes depending on whether they are mono-allelic or bi-allelic. This supports a causal relationship between expression level in the germline and phenotype variation. As a model to study this relationship, our study aimed to define the pathogenic characteristics of a recurrent homozygous coding variant in PMS2 displaying an attenuated phenotype identified by clinical genetic testing in seven Inuit families from Northern Quebec.METHODS: Pathogenic characteristics of the PMS2 mutation NM_000535.5:c.2002A>G were studied using genotype-phenotype correlation, single-molecule expression detection and single genome microsatellite instability analysis.RESULTS: This PMS2 mutation generates a de novo splice site that competes with the authentic site. In homozygotes, expression of the full-length protein is reduced to a level barely detectable by conventional diagnostics. Median age at primary cancer diagnosis is 22 years among 13 NM_000535.5:c.2002A>G homozygotes, versus 8 years in individuals carrying bi-allelic truncating mutations. Residual expression of full-length PMS2 transcript was detected in normal tissues from homozygotes with cancers in their 20s.CONCLUSIONS: Our genotype-phenotype study of c.2002A>G illustrates that an extremely low level of PMS2 expression likely delays cancer onset, a feature that could be exploited in cancer preventive intervention.

genetics & heredity